Your browser is no longer supported. Please, upgrade your browser.
Settings
RARE Ultragenyx Pharmaceutical Inc. daily Stock Chart
RARE [NASD]
Ultragenyx Pharmaceutical Inc.
Index- P/E- EPS (ttm)-3.90 Insider Own1.50% Shs Outstand53.91M Perf Week3.13%
Market Cap3.69B Forward P/E- EPS next Y-4.56 Insider Trans-4.52% Shs Float52.63M Perf Month20.79%
Income-197.60M PEG- EPS next Q-1.76 Inst Own92.80% Short Float11.36% Perf Quarter48.73%
Sales51.50M P/S71.63 EPS this Y27.20% Inst Trans1.39% Short Ratio9.03 Perf Half Y-21.16%
Book/sh12.00 P/B5.70 EPS next Y30.70% ROA-25.40% Target Price73.00 Perf Year33.50%
Cash/sh8.53 P/C8.02 EPS next 5Y17.20% ROE-29.30% 52W Range37.44 - 90.98 Perf YTD57.38%
Dividend- P/FCF- EPS past 5Y-18.10% ROI-61.10% 52W High-24.79% Beta2.19
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin97.80% 52W Low82.77% ATR2.97
Employees610 Current Ratio7.00 Sales Q/Q579.20% Oper. Margin- RSI (14)66.12 Volatility4.06% 5.33%
OptionableYes Debt/Eq0.00 EPS Q/Q-564.70% Profit Margin- Rel Volume0.62 Prev Close68.36
ShortableYes LT Debt/Eq0.00 EarningsFeb 19 AMC Payout- Avg Volume662.16K Price68.43
Recom1.90 SMA207.09% SMA5022.45% SMA2003.87% Volume412,248 Change0.10%
Feb-22-19Resumed Raymond James Outperform $80
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Nov-08-18Upgrade Citigroup Sell → Neutral
Sep-10-18Initiated Morgan Stanley Equal-Weight $92
Jun-21-18Downgrade Credit Suisse Outperform → Neutral
May-11-18Upgrade Barclays Equal Weight → Overweight $62 → $74
May-10-18Initiated Goldman Neutral $63
Apr-18-18Upgrade SunTrust Hold → Buy
Mar-22-18Resumed Piper Jaffray Overweight $67
Feb-21-18Reiterated Stifel Buy $85 → $74
Jan-22-18Upgrade Evercore ISI In-line → Outperform
Jan-18-18Initiated Credit Suisse Outperform $67
Dec-05-17Reiterated Barclays Equal Weight $60 → $62
Dec-04-17Upgrade Jefferies Hold → Buy
Sep-14-17Upgrade Wedbush Neutral → Outperform $62
Aug-23-17Downgrade SunTrust Buy → Hold $55
Aug-17-17Initiated Evercore ISI In-line $63
Aug-08-17Reiterated H.C. Wainwright Neutral $72 → $75
Apr-19-17Downgrade Wedbush Outperform → Neutral $80 → $75
Apr-19-17Downgrade H.C. Wainwright Buy → Neutral $88 → $72
Mar-11-19 08:30AM  Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
Feb-26-19 07:13PM  Ultragenyx Announces Pricing of Public Offering of Common Stock GlobeNewswire
Feb-25-19 04:01PM  Ultragenyx Announces Proposed Public Offering of Common Stock GlobeNewswire +5.93%
03:12PM  Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal Benzinga
09:21AM  MarketPulse: Roche's Bumper Deal for Spark Therapeutics Boosts Healthcare Stocks Investing.com
Feb-21-19 06:01PM  Edited Transcript of RARE earnings conference call or presentation 19-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
08:30AM  Ultragenyx Announces Positive 24-week Data from First Cohort of Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia GlobeNewswire
07:30AM  Report: Exploring Fundamental Drivers Behind Canopy Growth, Adobe, Ultragenyx Pharmaceutical, Humana, Ship Finance International, and NexGen Energy New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Feb-20-19 04:11PM  Here's Why This Small Biotech Stock Just Hit A Four-Month High Investor's Business Daily +6.55%
07:41AM  Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q4 Zacks
01:08AM  Ultragenyx Pharmaceutical Inc (RARE) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-19-19 06:33PM  Ultragenyx: 4Q Earnings Snapshot Associated Press
04:01PM  Ultragenyx Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Update GlobeNewswire
03:00PM  Ultragenyx Pharmaceutical, Inc. to Host Earnings Call ACCESSWIRE
Feb-14-19 08:30AM  Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH) GlobeNewswire
Feb-12-19 10:30AM  Will Ultragenyx (RARE) Report Negative Q4 Earnings? What You Should Know Zacks
08:30AM  Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update GlobeNewswire
Feb-06-19 01:07PM  Is Ultragenyx Pharmaceutical Inc.s (NASDAQ:RARE) Liquidity Good Enough? Simply Wall St.
Feb-04-19 08:30AM  Ultragenyx Appoints Shehnaaz Suliman, M.D., to Board of Directors GlobeNewswire
Jan-23-19 05:53PM  Ultragenyx's Fatty Acid Disorder Candidate Succeeds in Study Zacks
Jan-22-19 09:17AM  Ultragenyx stock up 2.9% after safety and efficacy trial reaffirms Phase 2 data MarketWatch
08:30AM  Ultragenyx Announces Positive Topline Data from Ongoing Long-Term Extension Study of UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders GlobeNewswire
Jan-17-19 09:06AM  J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect Zacks
Jan-11-19 07:30AM  New Research Coverage Highlights Arthur J. Gallagher, Ultragenyx Pharmaceutical, Empire State Realty Trust, ConocoPhillips, Kilroy Realty, and NETGEAR Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
06:55AM  Today's Research Reports on Trending Tickers: bluebird bio and Ultragenyx Pharmaceutical ACCESSWIRE
Jan-08-19 12:50PM  At biotech's big event, a chance for execs to shape LGBTQ diversity on boards American City Business Journals
Jan-06-19 04:51PM  JPM19 buzz-word bingo and the good, bad and ugly of biotech's big Union Square meetup American City Business Journals
09:32AM  Outlook For Battered Biotech Stocks In 2019 Investopedia
Jan-04-19 04:24PM  This Biotech Stock Is Flying On Its Promising Gene Therapy Investor's Business Daily +7.85%
08:30AM  Ultragenyx Announces Positive Topline Results from First Cohort of Phase 1/2 Clinical Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia GlobeNewswire
Jan-03-19 02:37PM  Analysts Issue New Ratings on Large Health Care Stocks GuruFocus.com
08:30AM  Ultragenyx to Present at J.P. Morgan Healthcare Conference GlobeNewswire
Dec-19-18 01:14AM  Hedge Funds Are Crazy About Ultragenyx Pharmaceutical Inc (RARE) Insider Monkey
Dec-13-18 07:00AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Ultragenyx Pharmaceutical ACCESSWIRE
Dec-06-18 08:30AM  Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita (burosumab injection) for the Treatment of Xlinked Hypophosphatemia (XLH) in Adults and Children GlobeNewswire
Dec-05-18 09:30AM  Ultragenyx (RARE) Down 7.2% Since Last Earnings Report: Can It Rebound? Zacks
Nov-21-18 01:52AM  Edited Transcript of RARE earnings conference call or presentation 5-Nov-18 10:00pm GMT Thomson Reuters StreetEvents +5.18%
Nov-14-18 08:30AM  Ultragenyx Announces Intent to Submit New Drug Application to U.S. FDA for UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Mid-2019 GlobeNewswire
Nov-09-18 08:30AM  Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
07:35AM  Report: Exploring Fundamental Drivers Behind AcelRx Pharmaceuticals, Fossil Group, FMC, Ultragenyx Pharmaceutical, Shenandoah Telecommunications, and Marcus & Millichap New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-06-18 04:31PM  Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q3 Zacks
12:30AM  Amazon, Pandora, PTC Therapeutics, and More: Why These Stocks Are Trending Insider Monkey
Nov-05-18 05:20PM  Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:15PM  Ultragenyx: 3Q Earnings Snapshot Associated Press
04:05PM  Ultragenyx Reports Third Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Nov-02-18 11:41AM  Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO Zacks
Oct-31-18 02:08PM  Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal Zacks
Oct-30-18 08:30AM  Ultragenyx to Host Conference Call for Third Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Oct-26-18 08:00AM  Ultragenyx Announces Negative Topline Results from Phase 3 Study of UX007 in Patients with Glut1 DS with Disabling Movement Disorders GlobeNewswire -18.09%
Oct-22-18 07:00AM  Ultragenyx Announces Exclusive License to REGENXBIO AAV Vectors to Develop Gene Therapy for CDD (CDKL5 Deficiency Disorder) GlobeNewswire
Oct-18-18 08:30AM  Ultragenyx Announces Approval of Mepsevii (vestronidase alfa) in Brazil for the Treatment of Mucopolysaccharidosis VII GlobeNewswire
Oct-03-18 07:50AM  Research Report Identifies Ultragenyx Pharmaceutical, Helmerich & Payne, Buckeye Partners, Covanta Holding, Summit Midstream Partners, LP, and Seattle Genetics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Sep-28-18 10:58AM  Ultragenyx Reports Top-line Data From Gene Therapy Candidate Zacks
Sep-27-18 07:00AM  Ultragenyx Announces Positive Topline Cohort 2 Results from Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency and Progression to Higher Dose GlobeNewswire -6.88%
Sep-26-18 08:30AM  Ultragenyx to Present at Jefferies Gene Therapy Summit GlobeNewswire
Sep-25-18 08:00AM  Today's Research Reports on Trending Tickers: Ultragenyx Pharmaceutical and FibroGen ACCESSWIRE
Sep-20-18 03:49PM  Ultragenyx's Shares Surge More Than 80% in the Year So Far Zacks
Sep-17-18 08:30AM  Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chief Operating Officer GlobeNewswire
Sep-06-18 08:00AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Ultragenyx Pharmaceutical ACCESSWIRE
Aug-30-18 09:50AM  Ultragenyx to File NDA for LC-FAOD Candidate on Existing Data Zacks
Aug-29-18 08:30AM  Ultragenyx Announces FDA Accepts Proposal to Submit an NDA for UX007 for the Treatment of Long-Chain Fatty Acid Oxidation Disorders GlobeNewswire +6.68%
Aug-28-18 05:45PM  Ultragenyx's Rare Disease Drug Mepsevii Gets EU Approval Zacks
Aug-27-18 04:01PM  Ultragenyx Announces Approval of Mepsevii (vestronidase alfa) in Europe for the Treatment of Mucopolysaccharidosis VII GlobeNewswire
Aug-23-18 01:55PM  Edited Transcript of RARE earnings conference call or presentation 2-Aug-18 9:00pm GMT Thomson Reuters StreetEvents -7.48%
Aug-03-18 05:38PM  Ultragenyx (RARE) Posts Narrower-than-Expected Loss in Q2 Zacks -9.77%
Aug-02-18 08:50PM  Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:46PM  Ultragenyx: 2Q Earnings Snapshot Associated Press
04:05PM  Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Jul-27-18 08:30AM  Ultragenyx to Host Conference Call for Second Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Jul-26-18 09:59AM  The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group Zacks
08:30AM  Ultragenyx Announces First Patient Dosed in Phase 1/2 study of DTX401, a Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa); FDA Grants Fast Track Designation to Gene Therapy Program GlobeNewswire
Jul-25-18 07:58AM  Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions Zacks
Jul-20-18 06:00AM  5 Favorite Biotech Bets Investopedia
Jun-29-18 09:00AM  Ultragenyx Announces Positive CHMP Opinion for Mepsevii (vestronidase alfa) For the Treatment of Mucopolysaccharidosis VII GlobeNewswire
Jun-19-18 07:30AM  Report: Developing Opportunities within Spartan Motors, Ultragenyx Pharmaceutical, Advanced Energy Industries, Verisk Analytics, Cogent Communications, and ADTRAN Future Expectations, Projections Moving into 2018 GlobeNewswire
Jun-14-18 12:33PM  Why Biotech Stocks May Reach New Highs Investopedia
Jun-07-18 07:35AM  Today's Free Research Reports Coverage on Seattle Genetics and Three More Biotech Stocks ACCESSWIRE
Jun-04-18 04:05PM  Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
May-29-18 08:20AM  Todays Research Reports on Stocks to Watch: Ultragenyx Pharmaceutical and BioMarin Pharmaceutical ACCESSWIRE
May-24-18 08:37AM  Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings Benzinga
May-23-18 05:01PM  Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of Medicine GlobeNewswire
May-17-18 08:30AM  Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH) GlobeNewswire
May-10-18 03:46AM  Edited Transcript of RARE earnings conference call or presentation 7-May-18 9:00pm GMT Thomson Reuters StreetEvents
May-07-18 04:26PM  Ultragenyx: 1Q Earnings Snapshot Associated Press +6.35%
04:05PM  Ultragenyx Reports First Quarter 2018 Financial Results and Corporate Update GlobeNewswire
12:30PM  Ultragenyx Pharmaceutical, Inc. to Host Earnings Call ACCESSWIRE
May-01-18 08:30AM  Ultragenyx to Host Conference Call for First Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Apr-30-18 08:30AM  Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in the U.S. for the Treatment of Xlinked Hypophosphatemia (XLH) in Children and Adults GlobeNewswire
Apr-25-18 08:10AM  Investor Expectations to Drive Momentum within MicroStrategy, Marcus & Millichap, Gentex, Ultragenyx Pharmaceutical, Dave & Buster's Entertainment, and Glatfelter Discovering Underlying Factors of Influence GlobeNewswire
Apr-23-18 08:30AM  Ultragenyx Announces Filing and FDA Clearance of an Investigational New Drug Application for DTX401, a Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia GlobeNewswire
Apr-18-18 02:19PM  Ultragenyx Pharmaceutical Wins Approval for Drug Treating Rare Form of Rickets TheStreet.com
11:14AM  2 Bay Area drug approvals in 1 day underscore industry's issues, opportunities American City Business Journals
Apr-17-18 03:19PM  Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza) for the Treatment of Children and Adults with X-Linked Hypophosphatemia (XLH) PR Newswire
01:25PM  Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza) for the Treatment of Children and Adults with XLinked Hypophosphatemia (XLH) GlobeNewswire
01:04PM  FDA approves Ultragenyx's treatment for rare type of rickets Reuters
Apr-16-18 06:10PM  North Bay company looks for 2nd rare-disease drug approval, voucher in 5 months American City Business Journals
Mar-08-18 08:00AM  Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
Mar-07-18 08:40AM  Ultragenyx says three patients in phase 1/2 gene therapy study had positive results MarketWatch
08:00AM  Ultragenyx Announces Positive Topline Results and DMC Review from First Cohort of Phase 1/2 Clinical Study of DTX301, an Investigational Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency GlobeNewswire
Mar-03-18 08:11PM  Edited Transcript of RARE earnings conference call or presentation 20-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing DTX701 that is in preclinical development for Wilson disease; UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Huizenga Theodore AlanVP, Controller and PAOJan 02Option Exercise21.002,44851,40814,505Jan 02 07:21 PM
Aliski WilliamDirectorDec 07Sale49.696,000298,14090,350Dec 07 04:12 PM
Aliski WilliamDirectorNov 08Sale55.676,000334,02096,350Nov 08 06:47 PM
Sharp ShaliniCFO & Executive Vice PresidentOct 31Option Exercise0.8212,0009,78062,128Oct 31 06:17 PM
Aliski WilliamDirectorOct 08Sale73.386,000440,280102,350Oct 09 04:36 PM
Sharp ShaliniCFO & Executive Vice PresidentSep 25Option Exercise0.823,3502,73056,828Sep 27 04:07 PM
Sharp ShaliniCFO & Executive Vice PresidentSep 25Sale90.076,700603,46950,128Sep 27 04:07 PM
Parschauer Karah HerdmanEVP and General CounselAug 21Sale78.535,000392,6509,181Aug 21 06:59 PM
Aliski WilliamDirectorAug 08Sale76.663,750287,47572,610Aug 08 05:32 PM
Parschauer Karah HerdmanEVP and General CounselJun 21Sale82.771,226101,47614,181Jun 21 05:32 PM
Huizenga Theodore AlanVP, Controller and PAOJun 15Option Exercise21.002,95562,05512,895Jun 15 07:55 PM
Huizenga Theodore AlanVP, Controller and PAOJun 15Sale83.7095579,93411,940Jun 15 07:55 PM
Huizenga Theodore AlanVP, Controller and PAOJun 13Sale76.971,338102,9869,940Jun 13 06:41 PM
Sharp ShaliniCFO & Executive Vice PresidentJun 07Option Exercise0.823,3502,73060,178Jun 07 07:17 PM
Sharp ShaliniCFO & Executive Vice PresidentJun 07Sale80.076,700536,45653,478Jun 07 07:17 PM
Sharp ShaliniCFO & Executive Vice PresidentMay 30Option Exercise0.826,5005,29870,174May 30 07:29 PM
Sharp ShaliniCFO & Executive Vice PresidentMay 30Sale70.1713,000912,17157,174May 30 07:29 PM
Fust Matthew KDirectorMay 30Sale72.006,319454,9698,750May 30 07:26 PM
Parschauer Karah HerdmanEVP and General CounselMay 10Sale60.001,46587,90016,056May 10 05:07 PM
Aliski WilliamDirectorApr 19Sale53.9765035,081108,350Oct 09 04:36 PM